Document G6n8m2kG0VZx8pQoZyEv3NE07

: sp! AR226-090% rrg5us7Siinion s| 908 tShiesyDre, Bd A | Hosham, PA 19044 PRIMEDICA 3 ECEIVE ORIGINAL wiism October 12,2000 MarviTn. Case, 3M Toxicology DV.M., Services PhD. 3St.MPCaeunlt,eMri,nBnueislodtian.g 252501-424E--100200 Telephone: Telefax: ((665511)) 773333--51178703 RE: Protocol 418009 - PCeorimnbaitnaledPoOsrtanalt(aGlavRaegper)odFeurcttiliiotny,TDoexviceiltoypmSetnudtyaolfanNd-E(FOSE in Rats Dear Dr. Case: Enclosed is a copy of the issued final Report Amendment 1 to theabove-referenced protocol fvou have any questions, please do not hesitate to contact me . Sincerely, RGYre Enc RaymobdG. York, PAD. DABT AasnsdocSitautdey DDiirreeccttoorrof Research = 28 5Z So0i8z e~ 7 prmedica Corparton |mow rimedic 29? ~-PRIMEDICA pA ee Tnoeon nE GEAe B ro Argus Research Laboratories. Inc REPORT AMENDMENT 1 12 OCTOBER 2000 PROTOCOL 418-009 PERINATCAOLM/PBOISNTENDAOTARLAL"R(EGPARVOADGUEC)TIFOERNTTIOLIXTIYC,ITDYEVSETLUODPYMOEFNNT-AELTFAONSDE IN RATS FINAL REPORT Attached is the corrected Text Figure 1 to the above-referenced final report. for the dosage administration ofthe F1 generation This changereflects rats and. did not tafhfeeacdtdtihteiornesoufltas nooftathteiosntudy. es me C4.2 fon t2:0ez00 Raytond G. York, PHL]. DABT Associate Director of Research Date and Study Director (rd Sithwos bo 2 VA |eNancy 1. Gongliewski Date {_/ Managerof Regulatory Compliance 280 Lo, 418-009PAGE 14 REVISED PAGE : lg ;{ iih g: h Ton I r. ii u--s ml L : hii I. ERE : Fa :iPT , ` : :----iw i| --CT# oku ; t NII hon bo --LT : i i il g : eee i i :: p:: ki:: !i iik: i PT 1 i | -- mo ui 1: A ui i : Hi : ee 261